Skip to content

Operating margin at other companies

Beam Therapeutics logo
Beam TherapeuticsBEAM
-226.6%-90.5pp
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
-3,020.3%-1,463pp
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
-720%-204pp
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-90.9%-19.8pp
Taysha Gene Therapies, Inc. logo
Taysha Gene Therapies, Inc.TSHA
-1,774.4%+1,437pp
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
-50.8%-1.6pp

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$43.8M-15.8%
Net income-$41.3M-15.0%
EPS (diluted)-$0.37+11.9%

Balance sheet

See full
Cash & equivalents$229.1M+283%
Total debt$5.6M+307%
Total equity$273.2M+35.6%
Total assets$293.6M+33.7%

Cash flow

See full
Operating cash flow-$36.9M+7.4%
CapEx$86.0K+330%
Free cash flow-$28.0M+52.6%

Valuation

See full
Market cap$1.82B+390%
Enterprise value$1.6B+414%

Profitability

See full
Gross margin100%+6.9pp
Net margin-45,096.2%-45,152pp
FCF margin-39,826.7%-39,847pp

Returns & leverage

See full
Return on equity-63.3%-12.2pp
Debt / equity0.0×
Current ratio17.9×+5.8×

Where this comes from

Calculated from Amylyx Pharmaceuticals, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 7, 2025, on SEC EDGAR. View the filing →

Ask your AI about Amylyx Pharmaceuticals, Inc.'s operating margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amylyx Pharmaceuticals, Inc.'s operating margin?
Amylyx Pharmaceuticals, Inc. (AMLX) reported operating margin of -47,349.8% in Q2 2025.
How has Amylyx Pharmaceuticals, Inc.'s operating margin changed year-over-year?
Amylyx Pharmaceuticals, Inc.'s operating margin decreased by 79480.1% year-over-year, from -59.5% to -47,349.8%.
What does operating margin mean?
Operating income as a percentage of revenue (trailing twelve months). Captures profitability from core operations after both cost of revenue and operating expenses, but before interest and taxes.